Evidence map›Paper›PMID 33536922›Full record

ArticleFrontiers in pharmacology2020

Editorial: Novel Drugs Targeting the Microenvironment and the Epigenetic Changes in Hematopoietic Malignancies.

Diana Gulei, Ciprian Tomuleasa, Liren Qian, Cristina Bagacean, Carlo M Croce, Gabriel Ghiaur

Open access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Extramedullary Hematopoiesis of the Liver and Spleen.Journal of clinical medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Diana GuleiMedfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Ciprian TomuleasaDepartment of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.
Liren QianDepartment of Hematology, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China.
Cristina BagaceanINSERM UMR1227, B lymphocytes and autoimmunity, University of Brest, Brest, France.
Carlo M CroceDepartment of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, United States.
Gabriel GhiaurDepartment of Leukemia, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.
Chinese PLA General Hospital · CNInserm · FRInstitute of Oncology Prof. Dr. Ion Chiricuta · ROIuliu Hațieganu University of Medicine and Pharmacy · ROSidney Kimmel Comprehensive Cancer Center · USThe Ohio State University · US

Funding

Cancer Gene Discovery to Identify Targetable TargetsR35CA197706 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M · 2015 to 2021
$6.4M
NCI NIH HHS R35 CA197706
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

epigenetic changeshematological malignancesmethylationpharmacologytumor microenvionment

Identifiers

PMID33536922
PMCPMC7849152
OpenAlexW3112153571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.